AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Breast Cancer: Fulvestrant is indicated for the treatment of HR-positive metastatic breast cancer in postmenopausal women who have not responded well to other hormone therapy treatments, such as tamoxifen or aromatase inhibitors. It works by binding to estrogen receptors on cancer cells, blocking the effects of estrogen, and causing degradation of the estrogen receptors.
Hormone Receptor-Positive Breast Cancer: Fulvestrant is particularly effective in treating breast cancers that are dependent on estrogen for growth. By blocking estrogen signaling, it helps slow down or stop the growth of cancer cells and may lead to tumor shrinkage.
Administration: Fulvestrant is administered via intramuscular injection into the buttocks. The recommended dose and frequency may vary depending on the specific treatment regimen prescribed by the healthcare provider.
Adverse Effects: Like any medication, fulvestrant may cause side effects. Common side effects include injection site reactions (such as pain, swelling, or redness), nausea, vomiting, headache, hot flashes, weakness, back pain, and joint pain. Some patients may also experience changes in liver function tests, which usually resolve with continued treatment.
Endocrine Effects: Fulvestrant works by blocking the estrogen receptor, leading to decreased estrogen signaling in the body. As a result, it may cause symptoms of estrogen deprivation, including vaginal dryness, decreased libido, and bone density loss (osteoporosis). Healthcare providers may monitor bone health and provide supplemental treatments, such as bisphosphonates, to prevent osteoporosis.
Cardiovascular Effects: There have been reports of cardiovascular events, including ischemic events (such as heart attacks) and thromboembolic events (such as blood clots), associated with fulvestrant use. Patients with a history of cardiovascular disease may require close monitoring during treatment.
Liver Function Monitoring: Fulvestrant may affect liver function, leading to increases in liver enzymes. Healthcare providers typically monitor liver function tests periodically during treatment to detect any abnormalities.
Drug Interactions: Fulvestrant may interact with other medications, particularly those metabolized by cytochrome P450 enzymes in the liver. Patients should inform their healthcare providers about all medications, supplements, and herbal products they are taking to avoid potential interactions.
Pregnancy and Breastfeeding: Fulvestrant is contraindicated during pregnancy and breastfeeding due to its potential to cause harm to the developing fetus or newborn. Women of childbearing potential should use effective contraception during treatment with fulvestrant.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Anaerobutyricum hallii | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 0 | 1 | Roseburia rectibacter | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 0 | 1 | Streptococcus sp. FDAARGOS_192 | species | Decreases |
| 0 | 1 | Butyrivibrio crossotus | species | Decreases |
| 0 | 1 | Blautia pseudococcoides | species | Decreases |
| 0 | 1 | Qiania dongpingensis | species | Decreases |
| 0 | 1 | Anaerobutyricum hallii | species | Decreases |
| 0 | 1 | Longicatena caecimuris | species | Decreases |
| 0 | 1 | Pseudobutyrivibrio xylanivorans | species | Decreases |
| 0 | 1 | Komagataeibacter oboediens | species | Decreases |
| 0 | 1 | Lachnoanaerobaculum gingivalis | species | Decreases |
| 0 | 1 | Ligilactobacillus ruminis | species | Decreases |
| 0 | 1 | Romboutsia ilealis | species | Decreases |
| 0 | 1 | Anaerostipes hadrus | species | Decreases |
| 0 | 1 | Blautia sp. SC05B48 | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| ADHD | 0.5 | 0.1 | 4 |
| Age-Related Macular Degeneration and Glaucoma | 0.2 | 0.1 | 1 |
| Allergic Rhinitis (Hay Fever) | 0.2 | 0.1 | 1 |
| Allergies | 0.1 | 0.1 | 0 |
| Allergy to milk products | 0.1 | 0.2 | -1 |
| Alzheimer's disease | 0.2 | 1.5 | -6.5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.1 | 0.1 | |
| Ankylosing spondylitis | 0.2 | 0.1 | 1 |
| Anorexia Nervosa | 0.1 | 0.6 | -5 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.1 | 4 |
| Asthma | 0.6 | 0.4 | 0.5 |
| Atherosclerosis | 0.1 | 0.7 | -6 |
| Atrial fibrillation | 0.4 | 0.5 | -0.25 |
| Autism | 0.6 | 1 | -0.67 |
| Autoimmune Disease | 0.1 | 0.2 | -1 |
| Barrett esophagus cancer | 0.1 | -0.1 | |
| benign prostatic hyperplasia | 0.1 | -0.1 | |
| Biofilm | 0.1 | 0.1 | |
| Bipolar Disorder | 0.2 | 0.2 | 0 |
| Brain Trauma | 0.1 | 0.3 | -2 |
| Cancer (General) | 0.2 | -0.2 | |
| Carcinoma | 0.3 | 0.2 | 0.5 |
| Celiac Disease | 0.6 | 0.3 | 1 |
| Cerebral Palsy | 0.2 | 0.3 | -0.5 |
| Chronic Fatigue Syndrome | 0.3 | 0.9 | -2 |
| Chronic Kidney Disease | 0.2 | 0.8 | -3 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 0.4 | -1 |
| Chronic Urticaria (Hives) | 0.1 | 0.1 | |
| Coagulation / Micro clot triggering bacteria | 0.1 | 0.3 | -2 |
| Cognitive Function | 0.2 | 0.3 | -0.5 |
| Colorectal Cancer | 0.6 | 0.5 | 0.2 |
| Constipation | 0.1 | 0.2 | -1 |
| Coronary artery disease | 0.3 | 0.7 | -1.33 |
| COVID-19 | 0.5 | 1.7 | -2.4 |
| Crohn's Disease | 0.6 | 0.9 | -0.5 |
| Cushing's Syndrome (hypercortisolism) | 0.1 | -0.1 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.4 | -0.4 | |
| Denture Wearers Oral Shifts | 0.2 | 0.2 | |
| Depression | 0.9 | 1.8 | -1 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.1 | 0.2 | -1 |
| Endometriosis | 0.2 | 0.3 | -0.5 |
| Eosinophilic Esophagitis | 0.1 | -0.1 | |
| Epilepsy | 0.2 | 0.3 | -0.5 |
| erectile dysfunction | 0.1 | 0.1 | |
| Fibromyalgia | 0.5 | 0.1 | 4 |
| Functional constipation / chronic idiopathic constipation | 0.8 | 0.4 | 1 |
| gallstone disease (gsd) | 0.1 | 0.2 | -1 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | -0.3 | |
| Generalized anxiety disorder | 0.2 | 0.2 | 0 |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.3 | 0.3 | |
| Graves' disease | 0.2 | 0.4 | -1 |
| Gulf War Syndrome | 0.1 | 0.1 | |
| Halitosis | 0.2 | 0.1 | 1 |
| Hashimoto's thyroiditis | 0.4 | 0.2 | 1 |
| Heart Failure | 0.3 | 0.5 | -0.67 |
| hemorrhagic stroke | 0.1 | 0.1 | |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| High Histamine/low DAO | 0.2 | 0.2 | |
| hyperglycemia | 0.1 | 0.2 | -1 |
| Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 0.4 | 0.6 | -0.5 |
| Hypoxia | 0.2 | 0.2 | |
| IgA nephropathy (IgAN) | 0.2 | 0.3 | -0.5 |
| Inflammatory Bowel Disease | 0.4 | 1.7 | -3.25 |
| Insomnia | 0.4 | 0.6 | -0.5 |
| Intelligence | 0.1 | 0.1 | |
| Intracranial aneurysms | 0.2 | 0.2 | |
| Irritable Bowel Syndrome | 0.4 | 0.5 | -0.25 |
| ischemic stroke | 0.2 | 0.5 | -1.5 |
| Liver Cirrhosis | 0.9 | 0.5 | 0.8 |
| Long COVID | 0.6 | 0.9 | -0.5 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.1 | 0.1 | 0 |
| Mast Cell Issues / mastitis | 0.1 | 0.1 | |
| ME/CFS with IBS | 0.1 | 0.2 | -1 |
| ME/CFS without IBS | 0.1 | 0.1 | 0 |
| membranous nephropathy | 0.1 | 0.1 | |
| Menopause | 0.2 | 0.2 | 0 |
| Metabolic Syndrome | 0.8 | 0.7 | 0.14 |
| Mood Disorders | 1.1 | 1.3 | -0.18 |
| multiple chemical sensitivity [MCS] | 0.2 | 0.2 | |
| Multiple Sclerosis | 0.4 | 1 | -1.5 |
| myasthenia gravis | 0.1 | 0.2 | -1 |
| neuropathic pain | 0.4 | -0.4 | |
| Neuropathy (all types) | 0.1 | 0.3 | -2 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 0.7 | -0.17 |
| NonCeliac Gluten Sensitivity | 0.1 | 0.1 | 0 |
| Obesity | 0.6 | 1.1 | -0.83 |
| obsessive-compulsive disorder | 0.3 | 0.3 | 0 |
| Osteoarthritis | 0.4 | 0.2 | 1 |
| Osteoporosis | 0.3 | 0.2 | 0.5 |
| pancreatic cancer | 0.1 | 0.1 | 0 |
| Parkinson's Disease | 0.7 | 1.5 | -1.14 |
| Polycystic ovary syndrome | 0.6 | 0.5 | 0.2 |
| Premenstrual dysphoric disorder | 0.1 | -0.1 | |
| primary biliary cholangitis | 0.1 | 0.1 | 0 |
| Primary sclerosing cholangitis | 0.2 | 0.2 | 0 |
| Psoriasis | 0.1 | 0.7 | -6 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 0.6 | 0 |
| Rosacea | 0.2 | -0.2 | |
| Schizophrenia | 0.5 | 0.4 | 0.25 |
| scoliosis | 0.2 | -0.2 | |
| sensorineural hearing loss | 0.1 | 0.1 | |
| Sjögren syndrome | 0.1 | 0.3 | -2 |
| Sleep Apnea | 0.3 | -0.3 | |
| Slow gastric motility / Gastroparesis | 0.1 | 0.1 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.2 | |
| Stress / posttraumatic stress disorder | 0.4 | 0.4 | 0 |
| Systemic Lupus Erythematosus | 0.3 | 0.3 | 0 |
| Tic Disorder | 0.1 | 0.1 | |
| Tourette syndrome | 0.1 | 0.1 | 0 |
| Type 1 Diabetes | 0.2 | 0.6 | -2 |
| Type 2 Diabetes | 0.9 | 0.6 | 0.5 |
| Ulcerative colitis | 0.4 | 0.5 | -0.25 |
| Unhealthy Ageing | 0.2 | 0.6 | -2 |
| Vitiligo | 0.3 | 0.1 | 2 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
